Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | The future of cord blood transplant in leukemia treatment

Filippo Milano • 10 Dec 2023
ASH 2023
Leukemia

Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the future of cord blood transplant (CBT) in leukemia treatment. Despite the decrease in CBT due to long recovery times and risk of infection, Dr Milano highlights that this therapeutic option still has a future, especially considering its remarkable benefits in high-risk patients. Recent FDA approval of a CBT product may encourage its use in the clinical setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Filippo Milano

Improving transplant conditioning for complex patients with high-risk disease
1:18
Improving transplant conditioning for complex patients with high-risk disease
Filippo Milano • 18 Mar 2026
Non-HLA-matched pooled umbilical cord blood transplant in acute leukemias and MDS
1:48
Non-HLA-matched pooled umbilical cord blood transplant in acute leukemias and MDS
Filippo Milano • 18 Mar 2026
The changing role of cord blood transplantation in hematological malignancies
1:21
The changing role of cord blood transplantation in hematological malignancies
Filippo Milano • 18 Mar 2026
The long-term outcomes and QoL with treosulfan-based conditioning in hematological malignancies
1:05
The long-term outcomes and QoL with treosulfan-based conditioning in hematological malignancies
Filippo Milano • 1 Apr 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals